Gifts

I made a serious mistake in 2009 when I realised that the OVATURE trial was having trouble recruiting patients, but held onto my stock.  I was already concerned by the non-linear response to increased dosages in an earlier trial, but failed to appreciate that perhaps the drug was being blocked at some point.  And I should have worked out that even in a blinded study, hospitals and patients KNOW when they see great responses relative to standard outcomes; and that slow recruitment meant that no one was excited by results to date.  

This background explains why I have taken the time to learn as much as possible about Noxopharm.  If there are any red flags, I want to know.

I can honestly say that I have identified NO red flags.  The key points have all been positive:

• Whereas Idronoxil was inactivated in the OVATURE trial, blood analysis of patients in Georgia revealed that the same drug delivered by suppository was distributed throughout the body in an unadulterated form.
• Idronoxil delivered by IV or Oral route had a short half-life and was therefore excreted by the body before it had time to work. Idronoxil delivered by suppository has a long half-life and the only worry was that too much active drug might accumulate in the body.  The current DARRT-1 trial will establish which dose level is best.
• There have been no adverse advents attributable to NOX66.  Furthermore, patients treated with chemo plus NOX66 did not appear to suffer from the normal side effects one would see with chemo.
• There is evidence that NOX66 is capable of causing an abscopal response.
• Graham Kelly is working harder than ever, spending five days a week on Noxopharm matters, and two days on Nyrada.  His PSA is ZERO.

The share price has dropped, but we have seen this before.  Some investors who subscribed to the IPO at 20 cents might have panicked when the SP dropped to 13 cents, but those who had done their homework would have known that 13 cents was a gift.

We will know by August whether NOX66 plus external radiotherapy is able to shrink or eradicate irradiated tumours in a formal trial setting.  If the results are as good as I expect, the current SP of 83 cents will be another gift.